Hints and tips:
...Boehringer Ingelheim is building a new manufacturing plant but, says Dias of the EMA, “you don’t build a new site overnight”....
...Sanofi: Shares in the French drugmaker gained 2.5 per cent after it said it had “prevailed” in arbitration over heartburn drug Zantac against rival Boehringer Ingelheim....
...Boehringer Ingelheim declined to comment on the arbitration’s ruling. Sanofi did not immediately respond to requests for comment....
...Before that, it was marketed by the private drugmaker Boehringer Ingelheim from 2006 to 2017, Pfizer from 2000 to 2006, and GSK from 1995 to 1998....
...Ingelheim....
...The proposed deal will create the second-biggest player in the animal medicines sector by revenues, leapfrogging Merck and Boehringer Ingelheim, but remaining behind Zoetis, the industry leader that was...
...Engelbert Coster Tjeenk Willink, a former executive at German pharma group Boehringer Ingelheim, will become CEO on an interim basis, the board said....
...Engelbert Coster Tjeenk Willink, a former executive at German pharma group Boehringer Ingelheim, will take the chief executive role on an interim basis, the board said....
...Scientists first identified the significance of CGRP in migraines in the 1980s, but earlier drugs developed by US-based Merck and Boehringer Ingelheim were abandoned amid signs that they caused liver damage...
...But a so-called “biosimilar” developed by Eli Lilly and Boehringer Ingelheim was approved by European regulators last month and the pair are pushing for its entry into the US....
...For example, Edwin Moses, head of Ablynx, a Belgian biotech company that has formed partnerships with AbbVie, Boehringer Ingelheim, Merck, Merck Serono and Novartis, highlights the scope for his company’...
...First in line will be flibanserin, a drug originally submitted to the FDA by Boehringer Ingelheim of Germany and rejected in 2010, on the grounds that its benefits did not outweigh side-effects....
...Boehringer Ingelheim, the pharmaceuticals company, in 2010 launched a €100m corporate VC fund and the same year RWE, the utility, consolidated existing VC activities into a new fund called Innogy Venture...
...Most of Vectura’s pipeline of drug formulations and new inhalers that have yet to come on the market have been licensed to Novartis, Boehringer Ingelheim, and Sandoz, the generics maker....
...Germany’s Bayer slipped 4.1 per cent to €42.32 after news reports suggested that rival group Boehringer Ingelheim might report strong data about a competing drug....
...Boehringer-Ingelheim has also grown at above-average industry rates....
...Some indigenous players remain, such as Boehringer Ingelheim, whose products include heart and Aids treatments....
International Edition